Bristol-Myers Squibb BMY Orencia — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's orencia — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's orencia — total revenues?
- Bristol-Myers Squibb (BMY) reported orencia — total revenues of $1.03B in Q2 2026.
- How has Bristol-Myers Squibb's orencia — total revenues changed year-over-year?
- Bristol-Myers Squibb's orencia — total revenues increased by 7.4% year-over-year, from $963M to $1.03B.
- What is the long-term trend for Bristol-Myers Squibb's orencia — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's orencia — total revenues has grown at a 2.9% compound annual growth rate (CAGR), from $3.31B to $3.71B.
- What does orencia — total revenues mean?
- This metric represents the total global net sales generated from the Orencia product line, a biologic therapy primarily used for the treatment of rheumatoid arthritis and other autoimmune conditions. It serves as a critical revenue stream within the company's immunology portfolio, reflecting market adoption and competitive positioning against alternative biologic treatments. Monitoring these revenues provides insight into the lifecycle stage of the drug and the company's ability to maintain market share in the highly competitive immunology space.